# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company's financial position; ...
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developi...
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ: CADL) with a Buy and maintains $...
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to place...
B of A Securities analyst Alec Stranahan downgrades Candel Therapeutics (NASDAQ:CADL) from Buy to Neutral and lowers the pri...